High mobility group box 1 (HMGB1) protein functions in regulation of transcription, cellular activation and pro-inflammatory responses. However, the potential role of HMGB1 during viral infection has not been investigated. This study attempted to elucidate whether the HMGB1-mediated inflammatory response contributes to the pathogenesis of dengue virus (DENV) infection. Our data showed that HMGB1 was released at low DENV infection levels (m.o.i. of 1) under non-necrotic conditions by human dendritic cells (DCs). When DENV-infected DCs were co-cultured with autologous T cells, there was increased production of HMGB1 by both cell types. HMGB1 regulated tumour necrosis factor alpha, interleukin (IL)-6, IL-8 and alpha interferon secretion in DENV-infected DCs. Additionally, increased HMGB1 production was associated with reduced DENV replication titres in DCs. These results suggest that HMGB1 production influences DENV infection in susceptible hosts.
INTRODUCTION
High mobility group box 1 (HMGB1) is a highly conserved protein with dual functions. As a nuclear DNA-binding protein HMGB1 functions in regulation of transcription, whereas in the extracellular milieu it is involved in cellular activation and pro-inflammatory responses (Andersson et al., 2000 (Andersson et al., , 2002 Czura & Tracey, 2003; Czura et al., 2001; Muller et al., 2001; Scaffidi et al., 2002; Wang et al., 1999a; Yang et al., 2001) . There are two known mechanisms by which HMGB1 may be released into the extracellular milieu. Firstly, it may be released passively by necrotic and damaged somatic cells and/or secondly, it may be actively released by macrophages/monocytes in response to exogenous and endogenous inflammatory stimuli. Once in the extracellular space, HMGB-1 can interact with advanced glycation end products (RAGE), as well as Toll-like receptor (TLR) 2 and TLR4 (Pisetsky, et al., 2008) . HMGB1 activates macrophages/monocytes and endothelial cells to express pro-inflammatory cytokines, chemokines and adhesion molecules (Bianchi & Manfredi, 2007; Dumitriu, et al., 2005; Messmer, et al., 2004; Parrish & Ulloa, 2007) . HMGB1 has been established as a critical mediator of lethal systemic inflammation as it plays an important role as a late mediator of lethal endotoxaemia and sepsis (Bianchi & Manfredi, 2007; Chen, et al., 2005; Dumitriu, et al., 2005) . Anti-HMGB1 antibodies have been shown to protect mice in a dose-dependent manner against lethal endotoxaemia (Wang et al., 1999a) and endotoxin-induced acute lung injury (Ueno et al., 2004) . Neutralizing antibodies against gamma interferon (IFN-c), one of the cytokines that induces HMGB1, have been shown to significantly reduce circulating levels of HMGB1 in septic rats and consequently to rescue rats from lethal sepsis (Yin et al., 2005) . Other agents such as glycyrrhizin, ethyl pyruvate, stearoyl lysophosphatidylcholine or nicotine have also been shown to dose-dependently inhibit HMGB1 release, thereby conferring protection against lethal sepsis (Mollica et al. 2007; Chen et al., 2005; Ulloa et al., 2002; Wati et al., 2007) .
The role of HMGB1 during viral infection is not known. Some viruses elicit inflammatory responses without being directly cytopathic. In certain circumstances, excess production of pro-inflammatory cytokines causes harm, thus facilitating injurious inflammatory responses. For example, at low infectious doses, West Nile virus (WNV) induces apoptotic death of infected cells in vitro. However, at higher doses, WNV has been shown to induce necrotic cell death, causing HMGB1 to be passively released into the extracellular space (Chu & Ng, 2003) . Accumulation of HMGB1 led to an injurious inflammatory response that may contribute to the pathogenesis of WN encephalitis. Similarly, there is increasing evidence that immune responses contribute to the outcome of dengue infections. Dengue virus (DENV) infection causes a relatively mild and self-limited dengue fever (DF), but some patients may develop dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS), the severe form of infection which often leads to death (Kurane, 2007; Pang et al., 2007) . The mechanism of DHF/DSS pathogenesis is still unclear. It is important to note, however, that life-threatening symptoms do not correlate with the period of high viraemia but instead they occur at a time when the virus load is in decline (Vaughn et al., 2000) . The manifestation of severe disease at the same time as defervescence suggests that DHF/DSS may be a consequence of the immune response to the virus rather than virus-induced cytopathology. The immunopathological mechanisms elicited by DENV in infected human hosts include secretion of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-a) that may play a key role in inducing unique clinical manifestations of DHF such as plasma leakage, shock and haemorrhaging (Kawahara et al., 2007; Pang et al., 2007) .
Since HMGB1 is a key promoter of pro-inflammatory cytokine production, we were interested in investigating the role of HMGB1 during dengue infection. A recent study by Chen et al., (2008) described HMGB1 induction during DENV infection in the epithelial cell line A549. In this study, a high level of DENV infection (m.o.i. of 10) was required to induce HMGB1 production, which was caused by cell necrosis. In the present study, we investigated HMGB1 release at low DENV infection levels (m.o.i. of 1) under non-necrotic conditions using human dendritic cells (DCs) and CD3
+ T cells as a model of DENV infection. Our studies showed that DENV infection promoted intracellular HMGB1 translocation from the nucleus to the cytosol in DCs and secretion of HMGB1 into surrounding supernatants in infected cultures. Furthermore, we demonstrated that HMGB1 plays a role in upregulating TNF-a, IL-6, IL-8 and IFN-a secretion by DENV-infected DCs and moderates DENV replication.
METHODS
Media and reagents. Complete RPMI medium consisted of RPMI 1640 medium, 1 % L-glutamine, 1 % penicillin and streptomycin, 1 % sodium pyruvate, 1 % essential amino acids, 50 mM 2-mercaptoethanol, and 10 % heat-inactivated fetal calf serum (Gibco-BRL). Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; 100 ng ml 21 ; Leukine; Immunex) and recombinant human IL-4 (rhIL-4; 50 ng ml
21
; R&D Systems) were added to the culture medium. Glycyrrhizin was purchased from Sigma-Aldrich. Recombinant HMGB1 protein was purchased from HMGBiotech. + cells were cultured for 7 days in complete RPMI (1 % L-glutamine, 1 % penicillin-streptomycin, 1 % sodium pyruvate, 1 % essential amino acids, and 10 % heat-inactivated fetal calf serum) in the presence of rhGM-CSF (100 ng ml 21 ) and rhIL-4 (50 ng ml 21 ) at 37 uC, 5 % CO 2 and 95 % relative humidity. On day 3, the culture medium was replaced with fresh medium supplemented with half the concentration of the original cytokines. Lactate dehydrogenase (LDH) assay. The release of LDH was detected using CytoTox 96 (Promega) in accordance with manufacturer's procedure (Miroslav et al., 1995) . Briefly, after supernatants were collected, they were centrifuged (Eppendorf Centrifuge 5418 with the fixed angle rotor FA-45-18-11 at 8000 r.p.m.) to obtain cellfree supernatants. Fifty microlitres of the sample per well was transferred to 96-well plates. LDH activity was detected by addition of freshly prepared reagents followed by incubation for 30 min in the dark at room temperature. The concentration of LDH was determined using an ELISA plate reader at an absorbance of 490 nm. The concentration of LDH was expressed as the fold increase in LDH activity from DENV-infected DCs with respect to that of mockinfected DCs.
HMGB1 quantification. HMGB1 was quantified by an ELISA performed according to the manufacturer's recommendations (Shino-test). Samples along with known standards and controls were assayed in triplicate. They were read on a SpectraMax 340 plate reader (Molecular Devices). The lower detection limit was 2.5 ng ml 21 .
Cytokine and chemokine assay. Using ELISA kits concentrations of TNF-a, IL-6, IL-8 (R&D Systems kit) and IFN-a (PBL Biomedical Laboratories kit) in culture supernatants were determined following the manufacturer's protocols. Samples along with known standards and controls were assayed in triplicate. They were read on a SpectraMax 340 plate reader (Molecular Devices). The lower detection limit was 5.1 pg ml 21 for TNF-a, 0.7 pg ml 21 for IL-6, 7.5 pg ml 21 for IL-8 and 12.5 pg ml 21 for IFN-a.
Quantitative RT-PCR. Quantitative RT-PCR (qRT-PCR) was performed as described by Sadon et al. (2008) with slight modifications. Primers and probe set used were those described for DENV-2. Each reaction contained 5 ml RNA suspension, 10 pmol of each DENV-2 primer and 5 pmol probe, 25 ml QuantiTect probe RT-PCR master mix (Qiagen), 0.5 ml QuantiTect RT-Mix (Qiagen) and 40 U RNase inhibitor (Promega) in a total volume of 50 ml. Prior to RT-PCR, the RNA was heated in the presence of primers to 65 uC for 10 min and transferred on ice before final reaction assembly. The single-step qRT-PCR consisting of a 30 min RT step at 50 uC, 15 min of Taq polymerase activation at 95 uC, followed by 40 cycles of PCR at 95 uC for 15 s and 60 uC for 1 min was performed on an ABI Prism 7900 sequence detection systems (SDS, Applied Biosystems). Accumulation of PCR products was detected by monitoring the fluorescence emitted by probe hydrolysis using SDS software. The amplification cycle (C T value) at which fluorescence was detected above the threshold was determined. A sample was defined as positive if the C T value was ,40, based on background cross-reactivity of the primers and probes in non-template control reactions. The number of copies of RNA per sample was derived from standard curves of serial dilutions of in vitro RNA transcripts (IVTs).
Blocking experiments. To investigate the role of HMGB1 in proinflammatory induction of TNF-a, IL-6 and IL-8 in DC, DENVinfected DCs were treated with anti-HMGB1 antibodies (8 mg ml
; Abcam) and the isotype control or 0.1 mM glycyrrhizin (SigmaAldrich). After the treatments, DCs were incubated for 24 h postinfection and supernatants were assayed for TNF-a, IL-6, IL-8 and IFN-a protein concentrations.
Confocal microscopy. After washing DCs and/or T cells twice with PBS, cells were centrifuged onto coverslips and then fixed with 2 % formaldehyde-0.1 % saponin-PBS for 20 min. Non-specific sites were blocked with 1 % goat serum-0.1 % saponin for 1 h. Cells were incubated for 24 h at room temperature with anti-HMGB then washed and incubated with goat anti-mouse IgG-FITC for 2 h. After washing, the cells were mounted onto slides with Vectashield and nail polish and then viewed with a Bio-Rad Radiance 2100 confocal microscope using a 606 oil immersion objective.
Statistics. When necessary, the results were expressed as means±SD. A paired Student's t-test was used to determine the difference which was thought to be significant when P,0.05.
RESULTS
DENV infection causes translocation of nuclear HMGB1 into the cytosol and secretion into the extracellular milieu
To determine whether DENV infection induces migration of HMGB1 from the nucleus to the cytoplasm, we analysed HMGB1 localization in mock-infected DCs or DENVinfected (m.o.i. of 1) DCs by immunofluorescent confocal microscopy. Fig. 1(a) shows localization of HMGB1 in the nucleus of the mock-infected DCs as opposed to distribution in both the nucleus and cytoplasm in DENV-infected DCs (Fig. 1b) . Furthermore, HMGB1 was secreted from the cytoplasm of infected DCs into the extracellular environment in a dose-dependent manner with increase in m.o.i. as indicated by the presence of HMGB1 in the supernatants after 120 h post-infection (Fig. 1c) . Intracellular double staining of HMGB1 and DENV showed that HMGB1 was expressed by both infected and uninfected DCs (Fig. 1d) . Note that in mock-infected DCs, HMGB1 was also detected intracellularly, but the level was lower than that of DENV-infected DC cultures.
DC-T cell co-cultures produced high amounts of HMGB1 which originate from both cell types HMGB1 secretion levels in co-cultures of DENV-infected or mock-infected DC-T cells were assessed since this interaction may have in vivo relevance. HMGB1 secretion sustains the proliferation of antigen-specific T cells, prevents their activation-dependent apoptosis, and promotes development of a T-helper 1 phenotype (Bianchi & Manfredi, 2007; Messmer et al., 2004) . Supernatants were harvested from DC-T cell co-cultures and T-cell-only cultures which were sustained by IL-2. DENV-infected DCs in the co-cultures were infected with virus at an m.o.i. of 1. A significantly higher amount of HMGB1 was present in DENV-infected DC-T cell co-culture compared with DENV-infected DCs (m.o.i. of 1) only cultures, mockinfected DC-T cells co-cultures or T-cell-only cultures. Interestingly, T cell cultures also produced HMGB1 (Fig. 1c) . In addition, the cytoplasmic distribution of HMGB1 was evident in T cells by confocal microscopy (data not shown).
There is probably active secretion of HMGB1 at low infection rates
We have previously shown that at low m.o.i. (m.o.i. of 1), apoptosis in DENV-infected DC cultures did not show significant differences from that in mock-infected DC cultures (Palmer et al., 2005) . However, cultures infected at a higher m.o.i. (m.o.i. of 5) resulted in an increase in the numbers of apoptotic cells. A study by Chen et al. (2008) showed that at an m.o.i. of 10, DENV causes necrosis and passively releases HMGB1 in epithelial cells. Since our data indicated that there was an increase in HMGB1 when DCs were infected with DENV, we evaluated whether HMGB1 was being released due to loss of cell membrane integrity by assessing LDH activity in DENV-infected cultures. LDH is a stable cytosolic enzyme that is released into the extracellular milieu upon cell lysis. LDH activity was analysed in the same supernatants as those assessed for HMGB1 from Fig. 1(c). At a low m.o.i. (m.o.i. of 1) , we observed similar levels of LDH in DENV-and mockinfected DC cultures (Fig. 2a) , suggesting the likelihood of active secretion of HMGB1 in DENV-infected DCs. However, when DCs were infected with high infectious doses, there was a remarkable increase in LDH activity (more than 10-fold increase at an m.o.i. of 10 and 14-fold increase at an m.o.i. of 100). To further investigate, LDH activity was analysed in DC-T cell co-cultures at ratios of 1 : 1, 1 : 10 and 1 : 70 at various times post-infection (Fig. 2b) . LDH activity remained mostly unchanged at 1 : 1 but increased at 1 : 10 and 1 : 70 and with increased incubation. There was a correlation between LDH activity and HMGB1 production (data not shown).
HMGB1 plays a role in upregulation of TNF-a, IL-6, IL-8 and IFN-a in DENV-infected DCs HMGB1 regulates secretion of pro-inflammatory cytokines (Libraty et al., 2001; Muller et al., 2001) . Additionally, recent work suggests that HMGB1 binds and enhances the pro-inflammatory property of secreted cytokines (Sha et al., 2008) . Studies have shown that DENV-infected DCs secrete large amounts of TNF-a and IFN-a (Palmer et al., 2005; Nightingale et al., 2008) as well as IL-6 and IL-8 (Nightingale et al., 2008) . HMGB1 plays a role in upregulating LPS-induced TNF-a, IL-6 and IL-8 gene expression, and protein production in monocytes/ macrophages (El Mezayen et al., 2007) . In addition, recombinant HMGB1 has been shown to induce low production of IFN-a in plasmacytoid DCs (Dumitriu et al., 2005) . To determine whether HMGB1 plays a role in upregulating TNF-a, IL-6, IL-8 and IFN-a production in DENV-infected DCs, experiments were performed to inhibit HMGB1 activity using specific antibodies to HMGB1 and glycyrrhizin, a small molecule known to specifically interact with soluble HMGB1 molecules (Mollica et al., 2007) . Biological agents such as anti-HMGB1 antibodies and compounds such as glycyrrhizin directly bind to extracellular released HMGB1, blocking its extracellular cytokine activities. Fig. 3 shows that anti-HMGB1 antibodies or glycyrrhizin decreased DENVinduced production of TNF-a, IL-6, IL-8 and IFN-a, suggesting that HMGB1 plays a role in production of these cytokines during DENV infection.
Elevated level of HMGB1 lowers the rate of DENV replication in DCs
A recent study showed that exogenous HMGB1 inhibited replication of human immunodeficiency virus in monocyte-derived macrophages (Nowak et al., 2006) . To investigate whether HMGB1 plays a role in modulation of viral replication in DENV-infected DCs, DENV replication was evaluated in DCs in the presence of exogenous HMGB1. Virus production in supernatants collected from infected cultures was assessed by qRT-PCR at 24 and 48 h post-infection and the average RNA copy number was obtained as described by Sadon et al. (2008) . As shown in Fig. 4(a) , the rate of viral replication was dosedependently reduced at 24 and 48 h post-infection with an increase in exogenous HMGB1. At 24 h, an increase of exogenous HMGB1 from 0 to 2500 pg ml 21 resulted in reduction of viral RNA copy from 3.0610 7 to 9.0610 5 . Similar inhibition was observed at 48 h. There was no difference in LDH activity (data not shown), which indicates that the difference in viral replication observed in DCs was not caused by compromised cell viability. Studies have shown that the IFN system plays an important role in limiting DENV replication both in vivo (Johnson & Roehrig, 1999; Shresta et al., 2004) and in vitro (Diamond et al., 2000; Diamond & Harris, 2001 ). Since we had observed reduction in DENV replication after addition of exogenous HMGB1, we wanted to further investigate whether this effect was associated with increased production of IFN-a. We assessed the presence of IFN-a in the supernatants from the above experiments using ELISA. Our data showed that increases in exogenous HMGB1 dose-dependently resulted in increased release of IFN-a (Fig. 4b) .
DISCUSSION
The present work was directed toward elucidating whether HMGB1-mediated inflammatory response contributes to the pathogenesis of DENV infection. It has been speculated that inflammatory responses mediated by active and/or passive release of HMGB1 contribute to pathogenesis of viral infections (Wang et al., 2006) . Viruses can induce necrotic cell death and/or trigger inflammatory responses (Chu & Ng, 2003; Fan & Zhang, 1994; Fan et al., 1998; Joseph et al., 2004; Julkunen et al., 2001) , which may lead to active and/or passive release of HMGB1. A recent study established that DENV infection elicits passive release of HMGB1 from necrotic epithelial cells infected at high m.o.i. (10) (Chen et al., 2008) .
In the present study, we have demonstrated for the first time, to our knowledge, that at an m.o.i. of 1, DENV infection causes translocation of HMGB1 from the nucleus into the cytosol and eventual secretion into the extracellular milieu. Consistent with the work by Chen et al. (2008) , we have demonstrated that at an m.o.i. ¢10, DENV infection induces necrosis in DCs and release of There was no detectable LDH activity in DENV-infected DC-T cell co-cultures incubated at ratio of 1 : 1. However, there was a marked increase in LDH activity after 72 h incubation at ratios of 1 : 10 and 1 : 70, with the 1 : 70 ratio co-cultures exhibiting the highest LDH activity. Values are means±SEM (error bars) from three independent experiments.
Role of HMGB1 in dengue infection in dendritic cells
HMGB1. Severe forms of DF, DHF and DSS are linked to overactivation of T cells (Kurane, 2007; Pang et al., 2007) , which are a major source of many of the pro-inflammatory cytokines associated with tissue damage during DHF/DSS. In this study, we demonstrated that T cells are an additional source of HMGB1 during DENV infection. Given that HMGB1 functions as a late mediator cytokine and/or enhancer of pro-inflammatory activities of other cytokines (Sha et al., 2008; Yang et al., 2001) , and that DENV induces HMGB1 release into the extracellular medium, the role of HMGB1 in DHF and DSS warrants further investigation. During infection or trauma, excessive production of extracellular HMGB1 causes multiple organ failure and can be more dangerous to the host than the original pathological manifestation (Mantell et al., 2006) . For example, excessive production of extracellular HMGB1 leads to vascular leakage and tissue hypoperfusion similar to that observed in sepsis (Abraham et al., 2000) . The pathological scenario associated with excessive HMGB1 production resembles those described in patients suffering from DHF/DSS. It has been suggested that vascular permeability defects leading to vascular leakage in both disease states may be the result of immune-mediated damage due to release of pro-inflammatory cytokines (Abraham et al., 2000) . Plasma of patients with DHF/DSS has elevated levels of cytokines. Some of the cytokines elevated in patients with DHF/DSS include TNF-a, IL-2, IL-6, IL-8, IL-10, IL-12, IFN-c and IFN-a (Avirutnan et al., 1998; Kurane et al., 1993; Libraty et al., 2002; Pang et al., 2007) . Cytokines have a complex interactive network of induction where they can induce the release and production of other cytokines. We demonstrated that secreted HMGB1 plays a role in upregulating TNF-a, IL-6, IL-8 and IFN-a cytokines produced in DENV-infected DCs. These cytokines also play a role in upregulation of HMGB1 (Wang et al., 1999b) . We propose that DENV infection induces a cascade of cytokines and other proteins such as HMGB1 which in a complex interactive network may lead to a cytokine storm associated with DHF and DSS. In this light, it would be interesting to further study the cascade of cytokine events associated with DHF/DSS and the role that HMGB1 might play.
It is likely that HMGB1 induced by DENV infection functions beyond pro-inflammation: it might play a role in functions such as maturation and migration. HMGB1 is involved in DC maturation (Messmer et al., 2004) and DENV infection induces DC maturation (Ho et al., 2001 ). Since our data showed that infecting DC with DENV induces HMGB1 production, it is plausible that one of the mechanisms by which DENV activates DCs to maturation is through induction of HMGB1. HMGB1 produced during DENV infection may also play a role in DC migration. A study by Yang et al. (2007) showed that HMGB1 induces migration of immature DCs but not mature DCs. Furthermore, they showed that DCs switched from CCL5-responsive to CCL21-responsive when they underwent HMGB1-induced phenotypic maturation. CCL21 is a chemokine that is secreted by secondary lymphoid tissues which stimulates chemokine receptors on the cell surface to direct DCs to migrate to the lymph nodes (Sallusto & Lanzavecchia, 2000) . We recently demonstrated that DENV infection causes DC migration by assessing the ability of infected cells to migrate to a CCL21 chemokine gradient (unpublished data). In these experiments, cell migration was carried out in 24-well polycarbonate transwell culture chambers. Cell migration towards CCL21 through the transwell pores was analysed after 4 h incubation by counting the number of cells from the bottom chamber. Therefore, a possible mechanism by which DENV-infection activates DC migration to lymph nodes is through upregulating HMGB1, a protein that is capable of recruiting or mobilizing DCs to its site of release, including T cells, and/or enhancing mature DC responsiveness to CCL21.
We have shown for the first time, to our knowledge, that HMGB1 modulates DENV replication in vitro. There are several mechanisms by which HMGB1 might exert such capabilities, including induction of other cytokines such as IFN-a and/or exerting its DNA binding properties. There is also a possibility that exogenous HMGB1 induces DC maturation, which might interfere with any one step of viral uptake and replication such as binding and/or internalization. Studies have showed that DENV titre decreases as fever days progress from fever to defervescence (Vaughn et al., 2000) . In septic patients, HMGB1 has been identified as a late mediator of endotoxin and is released days after endotoxin exposure (Ulloa et al., 2002) . DHF/ DSS patients have elevated levels of IFN-a (Kurane et al., 1993; Libraty et al., 2002) which might play a role in clearing virus titre in these patients. It is plausible that DENV infection induces HMGB1 production which might play a role in IFN-a production in DHF/DSS patients, one of the mechanisms by which HMGB1 might modulate DENV replication during dengue infection.
HMGB1 levels in serum of septic and haemorrhagic shock patients are elevated (Ombrellino et al., 1999; Sundén-Cullberg et al., 2005; Wang et al., 1999a) . However, the mechanism of HMGB1 release without infection is unknown, but it is attributed to active release from immune cells and/or leakage from damaged dying cells. HMGB1 is increasingly being shown to be a potent therapeutic target for experimental sepsis. For example, specific inhibition of endogenous HMGB1 therapeutically reverses lethality of established sepsis in mice . There are a large number of anti-inflammatory drugs in clinical use, but the mode of action of these drugs is not known. However, glycyrrhizin is one anti-inflammatory drug whose mode of action has recently been described; it binds directly to HMGB1 and inhibits its cytokine activities (Mollica et al., 2007) . Since the pathological scenario associated with excessive HMGB1 production resembles those described in patients suffering from DHF/DSS, it would be of interest in further studies to investigate how DHF/DSS patients respond to similar treatment.
In summary, we have shown that DENV induces DCs to produce HMGB1. Once produced, HMGB1 plays a role in induction of cytokines; this probably leads to a complex interactive network of induction where the released cytokines might further induce HMGB1 production. We have also discussed the need to further investigate the role of HMGB1 in DHF/DSS and the likelihood of applying septic shock treatments to DHF/DSS patients. It will be important to translate data obtained from this study to animal studies or clinical application since a large number of anti-inflammatory drugs are already in existence and widely used.
